Abstract
Original language | English |
---|---|
Article number | 5181 |
Journal | Nature communications |
Volume | 14 |
Issue number | 1 |
DOIs | |
Publication status | Published - 1 Dec 2023 |
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Nature communications, Vol. 14, No. 1, 5181, 01.12.2023.
Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Hepatic SREBP signaling requires SPRING to govern systemic lipid metabolism in mice and humans
AU - Hendrix, Sebastian
AU - Kingma, Jenina
AU - Ottenhoff, Roelof
AU - Valiloo, Masoud
AU - Svecla, Monika
AU - Sachdev, Vinay
AU - Kovac, Kristina
AU - Levels, Johannes H. M.
AU - Jongejan, Aldo
AU - de Boer, Jan F.
AU - Kuipers, Folkert
AU - Rimbert, Antoine
AU - Norata, Giuseppe D.
AU - Loregger, Anke
AU - Zelcer, Noam
AU - Zijlstra, Lobke F.
N1 - Funding Information: The present research has been conducted using summary statistics generated from the Global Lipids Genetics Consortium (http://www.lipidgenetics.org) and from the UK Biobank resource (under applications 26041, 48511, 49823 and 31063). We thank all participants of these cohorts and the research teams for making the data publicly available. We are grateful to the Bioinformatics Core Facility of Nantes BiRD, member of Biogenouest, Institut Français de Bioinformatique (IFB) (ANR-11-INBS-0013) for the use of its resources and for its technical support. The authors would like to thank Prof. Giangiacomo Beretta from the University of Milan for the kind help and assistance in processing the proteomics files in the OpenMS pipeline. NZ is an Established Investigator of the Dutch Heart Foundation (2013T111) and is supported by an ERC Consolidator grant (617376), an ERC Proof-Of-Concept grant from the European Research Council (862537) and by a Vici grant from the Netherlands Organization for Scientific Research (NWO; 016.176.643). We thank members of the Zelcer lab, Marten Hoeksema, Bart v/d Sluis, and Irith Koster for their critical comments and suggestions on this study. GDN is supported by: Progetti di Rilevante Interesse Nazionale [PRIN 2017 K55HLC], Ricerca Finalizzata, Ministry of Health [RF-2019-12370896], PNRR Missione 4, [Progetto CN3 - National Center for Gene Therapy and Drugs based on RNA Technology], PNRR Missione 4, [Progetto MUSA- Multilateral urban sustainability action], PNRR-MAD-2022-12375913. JFdB is supported by the Nutrition & Health initiative of the University of Groningen. AR is supported by a grant funded by the Agence Nationale de la Recherche (ANR-21- CE14-0051) for the GENESIS project. NZ is an Established Investigator of the Dutch Heart Foundation (2013T111) and is supported by an ERC Consolidator grant (617376), an ERC Proof-Of-Concept grant from the European Research Council (862537) and by a Vici grant from the Netherlands Organization for Scientific Research (NWO; 016.176.643). Funding Information: The present research has been conducted using summary statistics generated from the Global Lipids Genetics Consortium ( http://www.lipidgenetics.org ) and from the UK Biobank resource (under applications 26041, 48511, 49823 and 31063). We thank all participants of these cohorts and the research teams for making the data publicly available. We are grateful to the Bioinformatics Core Facility of Nantes BiRD, member of Biogenouest, Institut Français de Bioinformatique (IFB) (ANR-11-INBS-0013) for the use of its resources and for its technical support. The authors would like to thank Prof. Giangiacomo Beretta from the University of Milan for the kind help and assistance in processing the proteomics files in the OpenMS pipeline. NZ is an Established Investigator of the Dutch Heart Foundation (2013T111) and is supported by an ERC Consolidator grant (617376), an ERC Proof-Of-Concept grant from the European Research Council (862537) and by a Vici grant from the Netherlands Organization for Scientific Research (NWO; 016.176.643). We thank members of the Zelcer lab, Marten Hoeksema, Bart v/d Sluis, and Irith Koster for their critical comments and suggestions on this study. GDN is supported by: Progetti di Rilevante Interesse Nazionale [PRIN 2017 K55HLC], Ricerca Finalizzata, Ministry of Health [RF-2019-12370896], PNRR Missione 4, [Progetto CN3 - National Center for Gene Therapy and Drugs based on RNA Technology], PNRR Missione 4, [Progetto MUSA- Multilateral urban sustainability action], PNRR-MAD-2022-12375913. JFdB is supported by the Nutrition & Health initiative of the University of Groningen. AR is supported by a grant funded by the Agence Nationale de la Recherche (ANR-21- CE14-0051) for the GENESIS project. NZ is an Established Investigator of the Dutch Heart Foundation (2013T111) and is supported by an ERC Consolidator grant (617376), an ERC Proof-Of-Concept grant from the European Research Council (862537) and by a Vici grant from the Netherlands Organization for Scientific Research (NWO; 016.176.643). Publisher Copyright: © 2023, Springer Nature Limited.
PY - 2023/12/1
Y1 - 2023/12/1
N2 - The sterol regulatory element binding proteins (SREBPs) are transcription factors that govern cholesterol and fatty acid metabolism. We recently identified SPRING as a post-transcriptional regulator of SREBP activation. Constitutive or inducible global ablation of Spring in mice is not tolerated, and we therefore develop liver-specific Spring knockout mice (LKO). Transcriptomics and proteomics analysis reveal attenuated SREBP signaling in livers and hepatocytes of LKO mice. Total plasma cholesterol is reduced in male and female LKO mice in both the low-density lipoprotein and high-density lipoprotein fractions, while triglycerides are unaffected. Loss of Spring decreases hepatic cholesterol and triglyceride content due to diminished biosynthesis, which coincides with reduced very-low-density lipoprotein secretion. Accordingly, LKO mice are protected from fructose diet-induced hepatosteatosis. In humans, we find common genetic SPRING variants that associate with circulating high-density lipoprotein cholesterol and ApoA1 levels. This study positions SPRING as a core component of hepatic SREBP signaling and systemic lipid metabolism in mice and humans.
AB - The sterol regulatory element binding proteins (SREBPs) are transcription factors that govern cholesterol and fatty acid metabolism. We recently identified SPRING as a post-transcriptional regulator of SREBP activation. Constitutive or inducible global ablation of Spring in mice is not tolerated, and we therefore develop liver-specific Spring knockout mice (LKO). Transcriptomics and proteomics analysis reveal attenuated SREBP signaling in livers and hepatocytes of LKO mice. Total plasma cholesterol is reduced in male and female LKO mice in both the low-density lipoprotein and high-density lipoprotein fractions, while triglycerides are unaffected. Loss of Spring decreases hepatic cholesterol and triglyceride content due to diminished biosynthesis, which coincides with reduced very-low-density lipoprotein secretion. Accordingly, LKO mice are protected from fructose diet-induced hepatosteatosis. In humans, we find common genetic SPRING variants that associate with circulating high-density lipoprotein cholesterol and ApoA1 levels. This study positions SPRING as a core component of hepatic SREBP signaling and systemic lipid metabolism in mice and humans.
UR - http://www.scopus.com/inward/record.url?scp=85168722064&partnerID=8YFLogxK
U2 - https://doi.org/10.1038/s41467-023-40943-1
DO - https://doi.org/10.1038/s41467-023-40943-1
M3 - Article
C2 - 37626055
SN - 2041-1723
VL - 14
JO - Nature communications
JF - Nature communications
IS - 1
M1 - 5181
ER -